Page 244 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 244
Viral Hepatitis: Hepatitis C - Clinical (Except Therapy) (Cont.)
P0714 IMPACT OF PRIORITIZING TREATMENT IN A HIGH
RESOURCE SETTING - MINIMIZING THE BURDEN OF HCV
RELATED DISEASE IN 15 YEARS
Anne L. H. Øvrehus*, Sarah Blach, Peer B. Christensen, Jan Gerstoft,
Nina Weis, Henrik Krarup, Mette R. Clausen, Homie Razavi, Denmark
P0715 STEADY-STATE PHARMACOKINETICS AND SAFETY OF
COADMINISTRATION OF PAN-GENOTYPIC, DIRECT
ACTING PROTEASE INHIBITOR, ABT-493 WITH PAN-
GENOTYPIC NS5A INHIBITOR, ABT-530, IN HEALTHY
ADULT SUBJECTS
Chih-Wei Lin*, Wei Liu, Armen Asatryan, Andrew Campbell,
Weihan Zhao, Haoyu Wang, Dilraj Sidhu, Jack Clifton II, Jens Kort,
Sandeep Dutta, The United States
P0716 THE SIGNIFICANCE OF PLATELET MICROPARTICLES
IN PATIENTS WITH CHRONIC HEPATITIS C AND THEIR
ePOSTERS ASSOCIATION WITH ANTIVIRAL TREATMENT AND
SMOKING
Theoni Kanellopoulou, Alexandra Alexopoulou*, Flora N. Kontopidou,
Polydoros Konstantinidis, George V. Papatheodoridis, Greece
P0717 THE PRESENCE OF A PNPLA3 (RS738409) SINGLE
NUCLEOTIDE POLYMORPHISM (SNP) IS NOT ASSOCIATED
WITH INCREASED RISK FOR FIBROSIS, PORTAL
HYPERTENSION, AND HEPATIC STEATOSIS IN HIV/HCV-
COINFECTED PATIENTS
Bernhard Scheiner*, Mattias Mandorfer, Philipp Schwabl, Berit A. Payer,
Maximilian C. Aichelburg, Katharina Grabmeier-Pfistershammer,
Albert Stättermayer, Peter Ferenci, Michael Trauner, Markus Peck-
Radosavljevic, Thomas Reiberger, Austria
P0718 COST-EFFECTIVENESS OF INTERFERON-FREE THERAPY
FOR HEPATITIS C IN GERMANY - AN APPLICATION OF THE
EFFICIENCY FRONTIER APPROACH
Christian Gissel*, Georg Götz, Jörg Mahlich, Holger Repp, Germany
P0719 HEALTHCARE COSTS BY STAGE OF LIVER DISEASE IN
CHRONIC HEPATITIS C PATIENTS IN THE UNITED STATES
David R. Walker, Shivaji R. Manthena, Timothy R. Juday*,
The United States
244 The International Liver Congress™ 2015 • ILC Programme
P0714 IMPACT OF PRIORITIZING TREATMENT IN A HIGH
RESOURCE SETTING - MINIMIZING THE BURDEN OF HCV
RELATED DISEASE IN 15 YEARS
Anne L. H. Øvrehus*, Sarah Blach, Peer B. Christensen, Jan Gerstoft,
Nina Weis, Henrik Krarup, Mette R. Clausen, Homie Razavi, Denmark
P0715 STEADY-STATE PHARMACOKINETICS AND SAFETY OF
COADMINISTRATION OF PAN-GENOTYPIC, DIRECT
ACTING PROTEASE INHIBITOR, ABT-493 WITH PAN-
GENOTYPIC NS5A INHIBITOR, ABT-530, IN HEALTHY
ADULT SUBJECTS
Chih-Wei Lin*, Wei Liu, Armen Asatryan, Andrew Campbell,
Weihan Zhao, Haoyu Wang, Dilraj Sidhu, Jack Clifton II, Jens Kort,
Sandeep Dutta, The United States
P0716 THE SIGNIFICANCE OF PLATELET MICROPARTICLES
IN PATIENTS WITH CHRONIC HEPATITIS C AND THEIR
ePOSTERS ASSOCIATION WITH ANTIVIRAL TREATMENT AND
SMOKING
Theoni Kanellopoulou, Alexandra Alexopoulou*, Flora N. Kontopidou,
Polydoros Konstantinidis, George V. Papatheodoridis, Greece
P0717 THE PRESENCE OF A PNPLA3 (RS738409) SINGLE
NUCLEOTIDE POLYMORPHISM (SNP) IS NOT ASSOCIATED
WITH INCREASED RISK FOR FIBROSIS, PORTAL
HYPERTENSION, AND HEPATIC STEATOSIS IN HIV/HCV-
COINFECTED PATIENTS
Bernhard Scheiner*, Mattias Mandorfer, Philipp Schwabl, Berit A. Payer,
Maximilian C. Aichelburg, Katharina Grabmeier-Pfistershammer,
Albert Stättermayer, Peter Ferenci, Michael Trauner, Markus Peck-
Radosavljevic, Thomas Reiberger, Austria
P0718 COST-EFFECTIVENESS OF INTERFERON-FREE THERAPY
FOR HEPATITIS C IN GERMANY - AN APPLICATION OF THE
EFFICIENCY FRONTIER APPROACH
Christian Gissel*, Georg Götz, Jörg Mahlich, Holger Repp, Germany
P0719 HEALTHCARE COSTS BY STAGE OF LIVER DISEASE IN
CHRONIC HEPATITIS C PATIENTS IN THE UNITED STATES
David R. Walker, Shivaji R. Manthena, Timothy R. Juday*,
The United States
244 The International Liver Congress™ 2015 • ILC Programme
